BioSpace News Archive

KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high - throughput screening platform Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer Company is on t rack to s ubmit an IND in the fourth quarter of 2020 and i nitiate a Phase 1 /2 clinical trial

Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2020 on Monday, November 2 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the third quarter

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 29, 2020 to report its third quarter 2020 financial results and provide a corporate update.

- Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day - - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children’s Hospital -

F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2 ™) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer’s (SITC)

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute

--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia--

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the appointment of Niquette Hunt to its Board of Directors. Ms. Hunt currently serves as President and CEO of Candesant Biomedical.

Semler Scientific, Inc. (OTCQB: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020 . Doug Murphy-Chutorian , M.D., ch